Empiric Azithromycin in COVID-19 Impacts the Respiratory Microbiome and Antimicrobial Resistome without Anti-inflammatory Benefit.
Langelier C, Glascock A, Maguire C, Phan HV, Lydon E, Calfee C, Network I, Corry D, Kheradmand F, Baden L, Sekaly RP, McComsey G, Haddad E, Cairns C, Pulendran B, Fernandez-Sesma A, Simon V, Metcalf J, Higuita N, Messer W, Davis M, Nadeau KC, Kraft M, Bime C, Schaenman J, Erle D, Atkinson M, Ehrlich LIR, Melamed E, Montgomery R, Shaw A, Hough C, Geng L, Hoch A, Hafler D, Augustine A, Becker P, Peters B, Ozonoff A, Kim-Schulze S, Krammer F, Bosinger S, Eckalbar W, Altman M, Wilson M, Guan L, Maecker H, Steen H, Diray-Arce J, Rouphael N, Kleinstein S, Reed E, Levy O, Chu V.
Langelier C, et al. Among authors: wilson m.
Res Sq [Preprint]. 2025 Jun 20:rs.3.rs-6875205. doi: 10.21203/rs.3.rs-6875205/v1.
Res Sq. 2025.
PMID: 40585204
Free PMC article.
Preprint.